Prospective validity of measuring angina severity with Canadian Cardiovascular Society class: The ACRE study

BACKGROUND: Although the prevalence of angina remains high, the importance of grading angina severity is unclear. OBJECTIVES: To determine the extent to which angina severity is associated with angiographic findings, and the rate of revascularization, mortality and nonfatal myocardial infarction. METHODS: Prospective, population-based study with a 2.5-year follow-up of 2849 consecutive patients with angina undergoing coronary angiography at Barts and the London NHS Trust, London, United Kingdom, in the Appropriateness of Coronary Revascularisation (ACRE) study. Angina severity was assessed with the Canadian Cardiovascular Society (CCS) classification, ranging from class I (mild) to IV (severe). Outcome measures were revascularization rates, and all-cause mortality and nonfatal myocardial infarction. RESULTS: In age-adjusted analyses, a higher CCS class was linearly associated (P<0.001) with a higher number of diseased vessels and impaired left ventricular function. When adjusting for age, sex, smoking, history of hypertension, diabetes, number of diseased vessels, left ventricular function, use of acetylsalicylic acid, beta-blockers or statins, and revascularization status (for death and nonfatal myocardial infarction), a higher CCS class was linearly associated with higher coronary angioplasty (P<0.001) and bypass graft (P=0.03) rates, and lower all-cause mortality and nonfatal myocardial infarction (P<0.001; CCS IV versus I: hazard ratio 2.44, 95% CI 1.46 to 4.09). CONCLUSION: CCS class was linearly associated with angiographic findings, revascularization rates, mortality and nonfatal myocardial infarction. These findings support the importance of a four-level grading of symptom severity among angina patients.     

Canadian Cardiovascular Society classification of effort angina: an angiographic correlation

BACKGROUND: The Canadian Cardiovascular Society classification (CCSC) remains the standard for grading angina in patients with chronic stable angina. The utility value of this angina grading system in predicting the severity of coronary artery disease is not clear. AIM: We studied the relationship between the clinical angina grade and the angiographic severity of underlying coronary artery disease. MATERIALS AND METHODS: The participants in the study were 493 patients with stable angina who had undergone coronary angiography from 1998 to 2001. They were grouped according to their anginal grading and the number of vessels diseased. Significant lesions were defined as 50% narrowing for the left main and 70% for the left and right coronaries and their major branches. STATISTICAL ANALYSIS: The chi2-test was used for statistical analysis and a P-value <0.05 was taken as significant. RESULTS: There was no significant difference between the four angina class patients and the incidence of single-, double- and triple-vessel involvement. Class 1 patients had less left main trunk disease than class 4 patients. Class 3 and 4 patients had significantly fewer normal coronary angiograms. CONCLUSIONS: There is generally little correlation between coronary artery disease and the CCSC of effort angina except for left main disease. Presence or absence of angina rather than the CCSC should indicate the need for coronary angiography.     

Multivariate analysis of the long-term results of coronary artery bypass grafting performed during 1976 and 1977

The results of 492 consecutive coronary artery bypass grafting operations performed for angina in the 2-year period from 1976 to 1977 were evaluated 77 months after surgery. Follow-up was complete in 99%. In 80% of patients angina severity was New York Heart Association functional classes III or IV. An ejection fraction of less than 50% and left ventricular end-diastolic pressure of more than 15 mm Hg were each present in one-third of patients. Thirteen patients (2.6%) died in hospital and 70 (14%) died later during the follow-up period. Twenty-six reoperations were performed for recurrent angina (5.3%). Angina was initially relieved by operation in 97% of patients, but only 57% were alive and free of angina 6 years after their operation. Despite this, 91% of patients at last follow-up were in functional class I or II and 94% thought their symptoms were better than preoperatively. The mean postoperative time of onset of angina, estimated independently by family physicians and patients, was 33 months. The significant preoperative predictors of late death were a low left ventricular ejection fraction, previous myocardial infarction, prior cardiac surgery, increased cardiothoracic ratio and the number of coronary arteries with significant narrowing.     

Two-year outcomes in patients with mild refractory angina treated with enhanced external counterpulsation

BACKGROUND: In the International Enhanced External Counterpulsation Patient Registry (IEPR), approximately 85% of the patients treated are in Canadian Cardiovascular Society (CCS) class III-IV with no option for further invasive coronary revascularization procedures. HYPOTHESIS: This study sought to determine whether it is clinically important to establish whether the observed durable reduction in disabling severe angina with enhanced external counterpulsation (EECP) treatment can be extended to those with less severe CCS class II angina, who also have no option for further revascularization. METHODS: This study evaluated the immediate response, durability and clinical events over a 2-year period after EECP treatment in 112 patients with Canadian Cardiovascular Society (CCS) class II angina versus 1346 patients with class III-IV angina using data from the International EECP Patient Registry (IEPR). RESULTS: Treatment with EECP significantly (by at least one CCS class) reduced angina frequency, nitroglycerin use, and improved quality of life in both groups. At 2-year follow-up, 74% of class II and 70% of class III-IV patients remained free of major adverse cardiovascular events (MACE) and continued to demonstrate a durable CCS class improvement over baseline. CONCLUSION: The robust effectiveness of EECP as a noninvasive device, together with its relatively low start-up and recurrent costs, makes it an attractive consideration for treating patients with milder refractory angina in addition to the patient with severely disabling angina treated in current practice.     

Angina, aortic stenosis and coronary heart disease.

The pre-operative clinical and haemodynamic findings of 139 consecutive patients with aortic stenosis were analysed in an attempt to determine the incidence and influence of coronary heart disease on the mode of presentation of patients with aortic stenosis. The overall incidence of coronary heart disease was 32%. 105 patients (76%) presented with angina and of these, 41 patients (39%) had significant coronary heart disease as compared to 4 (13%) of the remaining 34 patients who did not present with angina. Clinical parameters including age, sex, severity of angina together with the presence of associated symptoms and precipitating factors were unhelpful in distinguishing those patients with coronary heart disease. Evidence of previous transmural myocardial infarction or the presence of ST-T abnormalities in the absence of digitalis and the changes of left ventricular hypertrophy were reliable electrocardiographic signs of coronary heart disease. Although peak systolic aortic valve gradient tended to decrease with increasing severity of coronary heart disease, the severity of aortic stenosis was not a reliable indicator of the presence of coronary disease. Patients with coronary heart disease in the absence of angina all had a combination of moderate aortic stenosis and single vessel disease. It is concluded that coronary heart disease cannot be predicted in patients with angina and, in the absence of angina occurs with an incidence sufficiently high to advocate the use of coronary angiography as part of the investigation of all patients with aortic stenosis being considered for valve replacement.     

The Canadian Cardiovascular Society grading scale for angina pectoris: is it time for refinements?

OBJECTIVE: To appraise the measurement properties of the Canadian Cardiovascular Society (CCS) classification of stable angina pectoris. DATA SOURCES: Relevant articles were identified through a MEDLINE search (1976 to November 1991). Bibliographies of retrieved articles were also reviewed. STUDY SELECTION: Studies chosen directly addressed the validity and reliability of the CCS scale. Recent studies and reviews of related topics (for example, silent ischemia) are selectively cited. DATA SYNTHESIS: No data address the scale's applicability, that is, how clinicians typically assign angina grades in practice. Comprehensiveness would be improved by coverage of the patient's perceptions of symptom burden; mixed exertional and rest symptoms; episodic or changing symptoms; and modifying factors. Reliability was assessed in one study with two clinicians; the interobserver, chance-corrected agreement on patient grading was 60%. Content validity (the ability of the scale to measure what it claims) is threatened by the unproven assumption of symptomatic or physiologic equivalence among diverse levels of different activities within any given grade of angina. Construct validity is uncertain, given weak relations between angina grade and noninvasive markers of ischemia, anatomical disease, or prognosis. The scale's responsiveness (the ability to detect the smallest clinically important changes) is limited by the reliance on four coarse gradations based on only ambulation or stair-climbing. CONCLUSIONS: The CCS scale for stable angina might be made more useful by developing measurements for patients' self-rated symptom burden and the changes they deem important; by adding items on clinical instability (that is, progressive symptoms or pain at rest); and by empirically testing the current scale to eliminate redundant or inconsistent elements.     

Relationship between parameters of heart rate variability,angiographical severity of coronary atherosclerosis and functional class of angina in patients with ischemic heart disease

AIM: To elucidate relationship between heart rate variability and severity of coronary atherosclerosis. MATERIAL: Seventy five patients with class I-IV angina subjected to coronary angiography and 23 apparently healthy subjects of the same age without overt coronary heart disease. METHODS: Analysis of parameters of variational pulsometry and heart rate entropy at rest and during test with controlled breathing (6 breaths/min). RESULTS AND CONCLUSION: Heart rate variability decreased with increase of functional class of angina and severity of coronary artery atherosclerosis. Within same functional class heart rate variability was lower in patients with more severe coronary atherosclerosis.     

经皮冠状动脉介入治疗缺血性心肌病合并严重左心功能不全的临床分析

目的:通过与药物治疗相比,评价经皮冠状动脉介入治疗(PCI)在缺血性心肌病合并严重左心功能不全患者中的疗效。方法:共入选156例合并严重左心功能不全(LVEF<35%)的缺血性心肌病患者,其中接受PCI治疗的患者65例,接受最佳药物治疗的患者91例。对所有患者进行30d和1年的随访,观察主要不良事件(MAE)包括全因死亡、ST段抬高型心肌梗死(STEMI)、急性心力衰竭、胃肠道出血、新出现的肾衰、脑出血;心绞痛(CCS分级)及心功能状态(NYHA分级)以及LVEF和左心室舒张末期直径(LVEDD);1年两组患者的存活率。结果:PCI组患者术后30 d及1年心绞痛分级均较药物治疗组明显降低(P<0.05)。虽然两组患者30d及1年的心功能分级和LVEF均有改善和提高,LVEDD均有缩小,但两组相比,差异无统计学意义(P>0.05)。PCI组患者30d的总MAE明显高于药物治疗组(13.8%vs.4.4%,P<0.05),主要表现为全因死亡、STEMI、急性心力衰竭的增加(P<0.05)。PCI组患者30 d存活率明显低于药物治疗组(95.4%vs.98.9%,P<0.05),PCI组患者1年的存活率低于药物治疗组,但差异无统计学意义(89.2%vs.93.4%,P>0.05)。结论:PCI相比药物治疗虽然可以改善合并严重左心功能不全的缺血性心肌病患者的心绞痛症状,但是短期全因死亡、STEMI、急性心力衰竭发生率较高,且不能明显改善患者的长期存活率。     

A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: the CCS-SAF scale

BACKGROUND: The severity of symptoms caused by atrial fibrillation (AF) is extremely variable. Quantifying the effect of AF on patient well-being is important but there is no simple, commonly accepted measure of the effect of AF on quality of life (QoL). Current QoL measures are cumbersome and impractical for clinical use. OBJECTIVE: To create a simple, concise and readily usable AF severity score to facilitate treatment decisions and physician communication. METHODS: The Canadian Cardiovascular Society (CCS) Severity of Atrial Fibrillation (SAF) Scale is analogous to the CCS Angina Functional Class. The CCS-SAF score is determined using three steps: documentation of possible AF-related symptoms (palpitations, dyspnea, dizziness/syncope, chest pain, weakness/fatigue); determination of symptom-rhythm correlation; and assessment of the effect of these symptoms on patient daily function and QoL. CCS-SAF scores range from 0 (asymptomatic) to 4 (severe impact of symptoms on QoL and activities of daily living). Patients are also categorized by type of AF (paroxysmal versus persistent/permanent). The CCS-SAF Scale will be validated using accepted measures of patient-perceived severity of symptoms and impairment of QoL and will require 'field testing' to ensure its applicability and reproducibility in the clinical setting. CONCLUSIONS: This type of symptom severity scale, like the New York Heart Association Functional Class for heart failure symptoms and the CCS Functional Class for angina symptoms, trades precision and comprehensiveness for simplicity and ease of use at the bedside. A common language to quantify AF severity may help to improve patient care.     

The internal logic of the Canadian Cardiovascular Society scale for grading angina pectoris: a first appraisal.

OBJECTIVE: To assess the internal logic (content validity) of the Canadian Cardiovascular Society (CCS) scale for grading angina pectoris. PATIENTS: Forty-one consenting patients with stable angina of at least two months duration, admitted to a tertiary centre for coronary angiography. METHODS: Patients completed a supervised questionnaire with closed-ended questions. Key questions included: usual numbers of blocks walked on the level or flights of stairs climbed before onset of chest pain; frequency with which chest pain occurred at the usual threshold distance; presence of rest pain; and influence of modifiers suggested for class II of the scale such as walking uphill and into the wind. RESULTS: Agreement of four questionnaire-defined 'stair-climbing grades' and 'walking grades' was statistically significant (P < 0.001) but only 37% better than expected by chance alone (weighted kappa). Frequency of angina at a patient's self-defined exercise threshold varied; only 22 of 41 patients (54%) had symptoms always or often. Higher classes of angina were more likely to be associated with frequent symptoms at threshold, eg, class I/II, six of 23 versus class III/IV, 16 of 17; 2P = 0.00002). Pain at rest was reported as 'definitely' present by 23 of 41 patients, and was similar in incidence across angina classes. All suggested modifiers reduced distances walked in a significant majority of patients (P values uniformly < 0.01) except for walking in the first few hours after awakening. However, the proportions of subjects for whom these factors were relevant were statistically similar for all angina grades, rather than for class II patients alone. CONCLUSIONS: These findings suggest that internal inconsistencies in the CCS scale are identifiable with simple validity checks. Further research appears warranted to improve this popular and useful clinical tool.     

血清非对称性二甲基精氨酸与冠心病严重程度的相关性

目的 探讨血清非对称性二甲基精氨酸（ADMA）水平与冠心病严重程度的相关性。方法 冠脉造影确诊的冠心病患者45例,依据冠心病临床类型分为急性心肌梗死组（n=22例）和心绞痛组（包括稳定型心绞痛和不稳定型心绞痛,n=23）。患者在入院后采集病史,测定心肌酶、三酰甘油（TG）、总胆固醇(TC)、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、高敏C反应蛋白（hs-CRP）和血清ADMA。同时用Syntax积分来评估冠脉狭窄程度,比较组间ADMA水平,分析ADMA水平与TG、TC、LDL-C、HDL-C、hs-CRP以及Syntax积分的相关性。结果 急性心肌梗死组血清ADMA水平(60±24) μg/L显著高于心绞痛组(31±21) μg/L,P<0.05。患者血清ADMA水平与LDL-C、hs-CRP呈正相关。患者血清ADMA水平与冠脉狭窄程度的Syntax积分呈正相关。结论 血清ADMA水平与冠心病严重程度有相关性。     

Enhanced external counterpulsation in the treatment of chronic refractory angina: a long-term follow-up outcome from the International Enhanced External Counterpulsation Patient Registry

BACKGROUND: The management of patients who suffer from medically refractory angina and are unsuitable for conventional revascularization therapy is often unsatisfactory. Enhanced external counterpulsation (EECP) is a noninvasive treatment that is safe and effective immediately after a course of treatment. However, the duration of benefit is less certain. HYPOTHESIS: To evaluate the 3-year outcome of EECP treatment. METHODS: One thousand four hundred and twenty seven patients from 36 centers registered in the International EECP Patient Registry (IEPR)-Phase 1 was prospectively followed for a median of 37 months. Two hundred and twenty patients (15.4%) died, while 1,061 patients (74.4%) completed their follow-up. RESULTS: The mean age was 66+/-11 years and 72% were men. Seventy-six percent had multivessel coronary disease for 11+/-8 years. Eighty-eight percent had a prior percutaneous or surgical revascularization and 82% were unsuitable for further coronary intervention.Immediately post-EECP, the proportion of patients with severe angina (Canadian Cardiovascular Angina Classification [CCS] III/IV) were reduced from 89% to 25%, p<0.001. The CCS class was improved by at least 1 class in 78% of the patients and by at least 2 classes in 38%. This was sustained in 74% of the patients during follow-up.Thirty-six percent of the patients had CCS II or less angina, which was better than pre-EECP state without a major adverse cardiovascular event during follow-up. More severe baseline angina and a history of heart failure or diabetes were independent predictors of unfavorable outcome. CONCLUSION: An EECP improves angina and quality of life immediately after a course of treatment. For most of the patients, these beneficial effects are sustained for 3 years.     

Significance of the antioxidant factor,thioredoxin, in heart failure

OBJECTIVES: Increases in oxidative stress may be involved in the progression of heart diseases. However, the serum levels of thioredoxin, a redox regulating protein, have been poorly investigated in patients with heart diseases. This study evaluated the clinical significance of the serum thioredoxin levels in patients with heart failure. METHODS: The serum thioredoxin levels were determined with a sandwich enzyme-linked immunosorbent assay in a total of 34 patients with dilated cardiomyopathy (n = 5), acute coronary syndrome (n = 7), and stable angina (n = 18), including effort angina (n = 7) and vasospastic angina (n = 11), and control subjects (n = 4). RESULTS: The serum thioredoxin levels were significantly elevated in patients with acute coronary syndrome (30.6 +/- 4.9 ng/ml, p < 0.001) and dilated cardiomyopathy (36.9 +/- 8.6 ng/ml, p < 0.001), but not in patients with stable angina (16.8 +/- 5.7 ng/ml, p = 0.27) compared with the control subjects (n = 4, 13.0 +/- 4.9 ng/ml). The serum thioredoxin level in patients with III and IV functional classes of the New York Heart Association (n = 8, 33.3 +/- 8.6 ng/ml, p < 0.001) was significantly higher than in the control subjects. In addition, the serum thioredoxin levels were negatively correlated with left ventricular ejection fractions of the patients (r = 0.59, p < 0.001). CONCLUSIONS: These results indicate a possible association between thioredoxin and the severity of heart failure.     

Percutaneous transmyocardial revascularization with holmium laser in patients with refractory angina: a pilot feasibility study.

BACKGROUND: Percutaneous transluminal myocardial revascularization (PTMR) is a new procedure to improve perfusion of the ventricular wall for patients with intractable angina that is untreatable by surgery or conventional catheter-based intervention. PTMR allows the creation of myocardial channels through the controlled delivery of holmium laser energy from the ventricular chamber. Preliminary studies in animals and human subject have yielded promising results. We now report the feasibility study of PTMR using a laser delivered through a novel Eclipse system, and we present the results of this sole therapy in patients with severe coronary disease and angina refractory to maximal medical treatment angina (III-IV CCS). METHODS: Percutaneous vascular access for PTMR treatment was obtained via the femoral artery. A 9F directional catheter carrying flexible fiber optics was used with a holmium laser (Eclipse system) and was placed across the aortic valve into the left ventricle cavity to create channels with a depth of 5 mm from the endocardial surface into the myocardial tissue. From April to November 1998, 15 patients underwent PTMR with Eclipse system. Two patients were female; the mean age was 66 +/- 8 (range 59-74). Five patients had a severe LV dysfunction (FE < 30%). Preoperative angina class was III in 10 patients and IV in 5 and previous myocardial procedures had been performed in all patients. RESULTS: The procedure was well tolerated and procedural success was obtained in 14 of 15 patients. There was one myocardial perforation because of guiding-catheter manipulation (pericardial drainage in fourth day). We performed a mean of 13 +/- 4 channels in a mean fluoro time of 23 +/- 11 min. Upon release and during follow-up (5.3 months +/- 4.2, range 2-10), angina class had significantly improved in 14 of 14 patients with complete PTMR treatment, with 4 asymptomatic patients, 6 patients in CCS I, 3 in CCS II, 2 in CCS III and only one patient hospitalized due to angina. CONCLUSION: This pilot study confirmed the safety and technical feasibility of PTMR. Immediate and short-term results confirm that a clinical improvement is obtained in most patients. Although these are early clinical benefits, the true efficacy of this approach will necessarily be defined by a randomized trials with prospectively-defined endpoints and with PTMR compared with medical therapy.     

SYNTAX评分和临床SYNTAX评分对冠心病患者接受经皮冠状动脉介入治疗后临床事件风险的预测价值

目的 评估SYNTAX评分(SXscore)和临床SYNTAX评分(CSS)对接受经皮冠状动脉介入治疗(PCI)术后15个月主要终点事件的预测价值.方法 共纳入547名接受择期PCI或直接PCI患者,记录病变SXscore和CSS评分,随访PCI术后终点事件发生情况,评估评分与事件的关系.结果 随访15个月,高、中、低SXscore三组主要不良心脑血管事件(MACCE)发生率分别为13.5%、6.8%及0.0%(P＜0.0001).控制混杂因素后,多因素回归分析显示,SXscore(RR=1.101,95%CI 1.070～1.134)及CSS(RR=1.017,95%CI 1.009～1.022)均是MACCE事件的独立预测因子(均为P＜0.0001).结论 SXscore评分和CSS评分是冠心病患者接受PCI术后MACCE事件的独立预测因子.     

State of the art approach to managing angina and ischemia: tailoring treatment to the evidence

Stable angina represents a chronic and often debilitating condition that affects daily activities and quality of life in patients with chronic coronary syndromes (CCS). Current European Society of Cardiology guidelines recommend a four-step approach for the medical treatment of patients taking into consideration hemodynamic variables (heart rate and blood pressure) and the presence or absence of left ventricular dysfunction. However, CCS patients often have several comorbidities and risk factors. Thus, a tailored approach that takes into consideration patient risk factors and comorbidities may have additional benefits beyond angina relief. This is a state of the art review of stable angina treatment based on the currently available evidence.     

Long-term prognosis of patients with myocardial bridge and angiographic milking of the left anterior descending coronary artery

INTRODUCTION: Myocardial bridging with systolic compression (milking) of the left anterior descending coronary artery may be associated with myocardial ischemia. Little information is available about the long-term prognosis of patients with this coronary anomaly. MATERIAL AND METHODS: A review was made of coronary angiographies of patients diagnosed as ischemic heart disease made between 1994 and 1999 in two centers. The long-term follow-up of patients with myocardial bridging and systolic compression of the left anterior descending coronary artery was analyzed. Data were collected by reviewing medical records and completed by telephone interview. RESULTS: Prevalence: 0.72%. Milking was observed in 60 patients, but 25 of them were excluded due to associated hypertrophic cardiomyopathy, severe valvular disease, or coronary artery disease. The clinical follow-up was available for all patients (median: 43 months, range: 12-80 months). Mean age 55.7 years (SD = 11.9). Men 74%. Clinical presentation: angina 26 patients, atypical chest pain with positive non-invasive test 8, acute myocardial infarction 1. During follow-up, 1 patient died of sudden cardiac death. Seven patients continued to present stable angina CCS class I-II, coronary angiography was repeated in 5 patients, and one required percutaneous revascularization for symptoms. In 63% of cases, antianginal drugs were still needed at the end of follow-up period (beta-blockers or calcium antagonists). CONCLUSIONS: Patients with myocardial bridging and systolic compression of the left anterior descending artery have a good long-term prognosis, although more than half of them continue regular treatment with antianginal drugs. In a small percentage of cases percutaneous intervention must be performed and ischemic heart disease may appear in more aggressive forms (acute myocardial infarction or sudden death).     

Increased circulating monocyte activation in patients with unstable coronary syndromes.

OBJECTIVES: The primary objective of this research was to assess the activation level of circulating monocytes in patients with unstable angina. BACKGROUND: Markers of systemic inflammatory responses are increased in patients with unstable coronary syndromes, but the activation state and invasive capacity of circulating monocytes have not been directly assessed. METHODS: Peripheral blood mononuclear cell (MC) activation in blood samples isolated from patients with stable and unstable coronary artery disease was measured in two studies. In study 1, a modified Boyden chamber assay was used to assess spontaneous cellular migration rates. In study 2, optical analysis of MC membrane fluidity was correlated with soluble CD14 (sCD14), a cellular activation marker. RESULTS: Increased rates of spontaneous monocyte migration (p < 0.01) were detected in patients with unstable angina (UA) (Canadian Cardiovascular Society [CCS] angina class IV) on comparison to patients with acute myocardial infarction (MI), stable angina (CCS angina classes I to III) or normal donors. No significant increase in lymphocyte migration was detected in any patient category. Baseline MC membrane fluidity measurements and sCD14 levels in patients with CCS class IV angina were significantly increased on comparison with MCs from normal volunteers (p < 0.001). A concomitant reduction in the MC response to activation was detected (p < 0.05). CONCLUSIONS: Using two complementary assays, activated monocytes with increased invasive capacity were detected in the circulation of patients with unstable angina. This is the first demonstration of increased monocyte invasive potential in unstable patients, raising the issue that systemic inflammation may both reflect and potentially drive plaque instability.     

Ranolazine for the treatment of refractory angina in a veterans population

BackgroundPivotal ranolazine trials did not require optimization of conventional medical therapy including coronary revascularization and antianginal drug therapy prior to ranolazine use. This case series describes the use of ranolazine for the treatment of chronic stable angina refractory to maximal medical treatment in a veterans population.ResultsA total of 18 patients with a median age of 66 years were identified. All patients had prior percutaneous coronary intervention and/or coronary artery bypass graft surgery; 83% had three-vessel coronary artery disease, with left main disease present in 39% of patients. Prior to initiating ranolazine, antianginal use consisted of beta blockers (94%), long-acting nitrates (83%) and calcium channel blockers (61%). Median blood pressure (116.2/61.8 mmHg) and pulse (65 beats per min) were controlled. Median preranolazine angina episodes and sublingual nitroglycerin (SLNTG) doses per week were 14 and 10, respectively, with a Canadian Cardiovascular Society (CCS) angina grade of III–IV in 67% of patients. After initiation of ranolazine, median angina episodes per week and SLNTG doses used per week decreased to 0.7 and 0, respectively, with CCS grade of III–IV declining to 17%. Of the 18 subjects enrolled, 44% had complete resolution of angina episodes.ConclusionThe addition of ranolazine to maximally tolerated conventional antianginal drug therapy post coronary revascularization was associated with decreases in angina episodes and SLNTG utilization and improvement in CCS angina grades. Ranolazine may provide an effective treatment option for revascularized patients with refractory angina.     

Serum thioredoxin (TRX) levels in patients with heart failure.

An increase in oxidative stress is thought to be involved in the progression of heart disease, but the serum level of thioredoxin (TRX), which regulates the cellular redox state, has not been investigated in patients with heart diseases. The present study determined serum TRX levels with a sandwich enzyme-linked immunosorbent assay in a total of 39 patients with dilated cardiomyopathy (DCM) (n=5), acute coronary syndrome (ACS) (n=7) or stable angina (n=18), including effort angina (n=7) and vasospastic angina (n=11), and in control subjects (n=7). The serum TRX level in patients with New York Heart Association (NYHA) functional classes III and IV (n=8, 33.3+/-8.6 ng/ml) was significantly higher than in the control subjects (n=7, 14.0+/-4.6 ng/ml). In addition, the serum TRX levels correlated positively with the severity of NYHA class, and negatively with the left ventricular ejection fraction. The serum TRX levels were elevated in patients with ACS and DCM compared with the controls. These results indicate a possible association between TRX concentration and the severity of heart failure.